+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Nivolumab"

Nivolumab Global Market Report 2024 - Product Thumbnail Image

Nivolumab Global Market Report 2024

  • Report
  • January 2024
  • 175 Pages
  • Global
From
Malignant Melanoma Treatment Global Market Report 2024 - Product Thumbnail Image

Malignant Melanoma Treatment Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Merkel Cell Carcinoma Treatment Global Market Report 2024 - Product Thumbnail Image

Merkel Cell Carcinoma Treatment Global Market Report 2024

  • Report
  • January 2024
  • 175 Pages
  • Global
From
Melanoma Drugs Global Market Report 2024 - Product Thumbnail Image

Melanoma Drugs Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
Advanced Merkel cell carcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Advanced Merkel cell carcinoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 80 Pages
  • Global
From
Metastatic Merkel Cell Carcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Metastatic Merkel Cell Carcinoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 90 Pages
  • Global
From
Metastatic Uveal Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Metastatic Uveal Melanoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
From
Ipilimumab + nivolumab Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Ipilimumab + nivolumab Drug Insight and Market Forecast - 2032

  • Report
  • November 2023
  • 30 Pages
  • Global
From
From
From
From
From
Opdualag (Nivolumab and Relatlimab) Drug Insight and Market Forecast - 2035 - Product Thumbnail Image

Opdualag (Nivolumab and Relatlimab) Drug Insight and Market Forecast - 2035

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
From
From
Loading Indicator

Nivolumab is a type of immunotherapy drug used to treat skin cancer. It is a monoclonal antibody that works by blocking the activity of a protein called PD-1, which helps cancer cells evade the body's immune system. Nivolumab is used to treat advanced melanoma, a type of skin cancer, and is approved for use in combination with other drugs. It is also being studied for use in other types of skin cancer, such as squamous cell carcinoma and basal cell carcinoma. Nivolumab is a relatively new drug, and is part of a growing class of immunotherapy drugs that are being used to treat cancer. It has been shown to be effective in treating advanced melanoma, and is being studied for use in other types of skin cancer. Some companies in the Nivolumab market include Bristol-Myers Squibb, Merck, and Roche. Show Less Read more